fbpx

Small Molecules in Oncology from Emerging Companies: 2021’s IPOs Pt. III

This article is Part 3 of a review series covering all of the initial public offerings for the biotech and pharmaceutical industries in 2021. Part 1 provided an overview of 2021 IPOs by therapy area, technology, and therapeutic class. Part 2 provided an overview of 2021 IPOs by therapeutic area.

This short article takes a deeper look into the 2021 IPOs for conventional small molecules being developed by oncology-focused companies including:

  • Companies by asset class of focus and primary indication
  • Lead molecules, mechanisms of action, and structures where available
  • Development stage at IPO
  • IPO proceeds
  • A company spotlight

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.



already a member? log in:

Join the Drug Hunter mailing list

to get free content and resources weekly. Trusted by > 5,500 drug hunters worldwide. Unsubscribe anytime.

This field is for validation purposes and should be left unchanged.
Newsletter

Join Subscribers from

…and hundreds more!